GMP lentiviral particle manufacturing facilities to produce gene & cell therapy drugs

While supplying high quality vectors for research and preclinical purpose (through the Vectalys platform), Flash Therapeutics is now accelerating its development by providing cGMP compliant lentiviral vectors production for clinical applications on two sites in Paris and Toulouse (France) for different phases in GMP process.

1. A GMP facility for small scale GMP grade lentiviral batches fully operational in 2019 through a three-year partnership between Flash Therapeutics and Saint-Louis Hospital.
2. Flash Therapeutics is building its own GMP facility in Toulouse to provide large scale GMP lentiviral vectors, which will be fully operational in 2020.

Both platforms will benefit from a strong & recognized 13-year track record in lentiviral vector manufacturing.

To learn more about our GMP offer, click here.